Neoleukin is a biopharmaceutical company creating next generation immunotherapies using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukinâs lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. For more information, please visit the Neoleukin website: www.neoleukin.com. Source
No articles found.
BioTelemetry, Inc. is the leading remote medical technology company focused on the...
BioTelemetry, Inc. is the leading remote medica...
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and ...
Catalyst Pharmaceuticals is a biopharmaceutical...
Equillium is a biotechnology company leveraging deep understanding of immunobiolog...
Equillium is a biotechnology company leveraging...
Titan is a specialty pharmaceuticals company that develops therapeutics for select...
Titan is a specialty pharmaceuticals company th...
Allakos is a clinical-stage company developing therapeutic antibodies that selecti...
Allakos is a clinical-stage company developing ...
Bayer is a global enterprise with core competencies in the life science fields of ...
Bayer is a global enterprise with core competen...
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new...
HOOKIPA Pharma Inc. is a clinical stage biophar...
Join the National Investor Network and get the latest information with your interests in mind.